Merck & Company, Inc. · NYSE:MRK

Merck & — Shareholder Meeting (May 2024)

29 slides from Merck &'s shareholder meeting presentation, May 28, 2024

1. Slide 1: Annual Meeting of Shareholders

   Annual Meeting of Shareholders May 28, 2024

2. Slide 2: Forward-looking Statement of Merck & Co., Inc.

   Confidential Forward-looking Statement of Merck & Co., Inc. This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements

3. Slide 3: Annual Meeting of Shareholders – Robert M. Davis

   Annual Meeting of Shareholders Robert M. Davis Chairman and Chief Executive Officer

4. Slide 4: Nominees for Director

   Confidential Nominees for Director Robert M. Davis Douglas M. Baker, Jr. Mary Ellen Coe Pamela J. Craig Thomas H. Glocer Risa J. Lavizzo- Mourey, M.D. Stephen L. Mayo, Paul B. Rothman, Patricia F. Russo Christine E. Inge G. Thulin Kathy J. Warden Ph.D. M.D. Seidman, M.D. 4

5. Slide 5: Celebrating retirement

   Confidential Board transition Celebrating retirement Peter C. Wendell 5

6. Slide 6: Executive team

   Confidential Executive team Robert M. Davis Sanat Chattopadhyay Richard R. DeLuca, Jr. Cristal N. Downing Chirfi Guindo Michael A. Klobuchar Betty Larson Dean Y. Li, M.D., Ph.D. Caroline Litchfield Jannie Oosthuizen Joseph Romanelli Dave Williams Jennifer Zachary 6

7. Slide 7: €> MERCK

   €> MERCK

8. Slide 8: Merck’s Purpose

   Merck’s Purpose For more than 130 years, Merck has been guided by one clear and compelling purpose: putting patients first and using the power of leading-edge science to save and improve lives. 8

9. Slide 9: Full-year 2023 highlights

   Confidential Full-year 2023 highlights Financial highlights (Non-GAAP)* Full Year Ex-Exchange Human Health sales 2023 % vs. Prior $53.6B +1% Sales $60.1 +4% +12% ex-exchange and LAGEVRIO PGM % 76.9% +3.1 ppts Strong growth in KEYTRUDA, GARDASIL/GARDASIL 9 and VAXNEUVANCE Operating Expense $40.0 +86%

10. Slide 10: Sustained momentum across pipeline

    Confidential Sustained momentum across pipeline Oncology Cardiometabolic Vaccines and Animal Health disease infectious diseases 10

11. Slide 11: Business development to complement strong pipeline

    Confidential Business development to complement strong pipeline Over $18B in business development* More than 75 significant agreements* *Figures for 2023 11

12. Slide 12: Sustainability that drives long-term success

    Confidential Sustainability that drives long-term success Access Inclusion Environmental

13. Slide 13: €9 MERCK

    €9 MERCK

14. Slide 14: Annual Meeting of Shareholders – Dean Y. Li

    Annual Meeting of Shareholders Dean Y. Li, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories

15. Slide 15: Shaping the future of oncology

    Confidential Shaping the future of oncology Immuno-oncology Precision molecular targeting Tissue targeting opevesostat2 patritumab deruxtcan3 MK-28704 (MK-5684) HER3 ADC TROP2 ADC CYP11A1 inhibitor MK-12004 MK-24003 9 FDA approvals bomedemstat B7H3 ADC Claudin 18.2 ADC based on trials conducted (MK-

16. Slide 16: Advancing our pipeline across therapeutic areas

    Confidential Advancing our pipeline across therapeutic areas Cardiometabolic HIV Immunology islatravir tulisokibart oral NRTTI treatment TL1A inhibitor MK-0616 MK-5475 MK-8527 MK-6194 novel oral inhaled sGC once-monthly oral IL-2 mutein PCSK9 inhibitor stimulator NRTTI PrEP VERQUVO MK-2060 MK-8504 s

17. Slide 17: Expanding our vaccines legacy

    Confidential Expanding our vaccines legacy Clinical development of new investigational multi-valent HPV vaccine. HPV Evaluation of efficacy and safety of single-dose GARDASIL 9 regimen vs. the approved three-dose regimen. Potential FDA approval of V116. Pneumococcal Readout for Phase 3 study of cles

18. Slide 18: €> MERCK

    €> MERCK

19. Slide 19: Nominees for Director

    Confidential Nominees for Director Robert M. Davis Douglas M. Baker, Jr. Mary Ellen Coe Pamela J. Craig Thomas H. Glocer Risa J. Lavizzo- Mourey, M.D. Stephen L. Mayo, Paul B. Rothman, Patricia F. Russo Christine E. Inge G. Thulin Kathy J. Warden Ph.D. M.D. Seidman, M.D. 19

20. Slide 20: €> MERCK

    €> MERCK

21. Slide 21: Proposal 4 – Shareholder Proposal

    Proposal 4 – Shareholder Proposal

22. Slide 22: €> MERCK

    €> MERCK

23. Slide 23: Proposal 5 – Shareholder Proposal

    Proposal 5 – Shareholder Proposal

24. Slide 24: €> MERCK

    €> MERCK

25. Slide 25: Proposal 6 – Shareholder Proposal

    Proposal 6 – Shareholder Proposal

26. Slide 26: €> MERCK

    €> MERCK

27. Slide 27: Question & Answer

    € MERCK Question & Answer

28. Slide 28: €> MERCK

    €> MERCK

29. Slide 29: Thank you

    Thank you Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. 29

Merck & — Shareholder Meeting (May 2024) on 6ix